← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
BioLife improved net loss, cash flow, debt, and equity, but insider sales and a wider operating loss kept the FY2025 read mixed.
The read at a glance✓ Audited against SEC data
- Business mix — Bioproduction toolsNote
- Gross profit — Gross profit up to $62.1MOK
- Loss — Net loss narrowed 77.2%OK
- FCF — FCF up to $10.6MOK
- Debt — Debt down 68.7%OK
- Insiders — 0 purchases / 63 salesWatch
- Accounting — Forensic screens unavailableNote
Business
BioLife Solutions provides bioproduction products and services used in biologic material manufacturing and delivery, with a focus on biopreservation media and cell-processing products.
Where the revenue comes from
Fiscal 2024, as BIOLIFE SOLUTIONS INC reports it. History and quarterly detail are in the app.
- Product$76.0M
- Product Cell Processing$73.4M
- Rental Revenue$6.1M
- Rental Evo And Thaw$6.1M
- Product Evo And Thaw$2.6M
Leadership changes
From BIOLIFE SOLUTIONS INC's own filings, the day they're filed.
- Catherine Coste · directors · departureeff. 2025-03-18
- Tony J. Hunt · Chairman · appointmenteff. 2025-01-02
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIOLIFE SOLUTIONS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.